DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

K Keun-Wook Lee (Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea) D Devalingam Mahalingam B Byoung Yong Shim I In-Ho Kim D Do-Youn Oh (Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, and the Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea) H Hope Uronis S Sun Jin Sym M Mohamad Sonbol K Khaldoun Almhanna M Mohamedtaki A. Tejani B Beodeul Kang M Michael H. Kagey M Melissa Stilian C Calvin Jia C Cynthia A. Sirard R Rachel Altura J Jaffer A. Ajani S Samuel J. Klempner (Mass General Brigham Cancer Institute, Boston)